TY - JOUR
T1 - Synergistic antinociceptive effect and gastric safety of the combination of docosahexaenoic acid and indomethacin in rats
AU - Arroyo-Lira, Arlette Guadalupe
AU - Rodríguez-Ramos, Fernando
AU - Chávez-Piña, Aracely Evangelina
N1 - Funding Information:
The authors acknowledge the support provided by the National Polytechnic Institute (Projects SIP-20141036 and SIP-SNI-2011/01 ) and the National Council for Science and Technology (Project CONACyT 178027 ). Arroyo-Lira Arlette Guadalupe is a CONACyT fellow (Grant Number 269377 ).
PY - 2014/7
Y1 - 2014/7
N2 - The use of analgesics is limited by the presence of significant adverse side effects. Thus, combinations of non-steroidal anti-inflammatory drugs (NSAIDs) with other antinociceptive agents are frequently used to decrease these adverse reactions. The aims of this work were to evaluate the antinociceptive interaction of the systemic administration of the combination of DHA and indomethacin through an isobolographic analysis of the theoretical and experimental antinociceptive effect and to demonstrate the gastric safety of the mixture compared with indomethacin alone. Female Wistar rats were orally administered indomethacin (1-10 mg/kg), DHA (100-300 mg/kg), or the DHA-indomethacin mixture at a fixed-ratio combination (1:1, 1:3, 3:1), and the antinociceptive effects of these treatments were evaluated through the formalin (1%) test. An isobolographic analysis was performed to characterize the antinociceptive interaction between DHA and indomethacin. The degree of gastric injury in all of the rats was determined 1 h after the formalin test. The theoretical ED30 values (Zadd) for the 1:1, 1:3, and 3:1 combinations were 73.48 ± 8.96, 37.75 ± 4.50, and 109.2 ± 13.43 mg/kg, p.o., respectively, and the experimental ED30 values (Zexp) were 43.63 ± 5.18, 13.13 ± 1.61, and 54.20 ± 6.53, respectively. The isobolographic analysis showed that the three fixed-ratio combinations studied exhibited a synergistic interaction. Furthermore, the gastric damage induced by indomethacin was abolished when this drug was combined with DHA. These data suggest that the systemic administration of the DHA-indomethacin combination induces a synergistic and gastric safety effect.
AB - The use of analgesics is limited by the presence of significant adverse side effects. Thus, combinations of non-steroidal anti-inflammatory drugs (NSAIDs) with other antinociceptive agents are frequently used to decrease these adverse reactions. The aims of this work were to evaluate the antinociceptive interaction of the systemic administration of the combination of DHA and indomethacin through an isobolographic analysis of the theoretical and experimental antinociceptive effect and to demonstrate the gastric safety of the mixture compared with indomethacin alone. Female Wistar rats were orally administered indomethacin (1-10 mg/kg), DHA (100-300 mg/kg), or the DHA-indomethacin mixture at a fixed-ratio combination (1:1, 1:3, 3:1), and the antinociceptive effects of these treatments were evaluated through the formalin (1%) test. An isobolographic analysis was performed to characterize the antinociceptive interaction between DHA and indomethacin. The degree of gastric injury in all of the rats was determined 1 h after the formalin test. The theoretical ED30 values (Zadd) for the 1:1, 1:3, and 3:1 combinations were 73.48 ± 8.96, 37.75 ± 4.50, and 109.2 ± 13.43 mg/kg, p.o., respectively, and the experimental ED30 values (Zexp) were 43.63 ± 5.18, 13.13 ± 1.61, and 54.20 ± 6.53, respectively. The isobolographic analysis showed that the three fixed-ratio combinations studied exhibited a synergistic interaction. Furthermore, the gastric damage induced by indomethacin was abolished when this drug was combined with DHA. These data suggest that the systemic administration of the DHA-indomethacin combination induces a synergistic and gastric safety effect.
KW - Analgesic
KW - Antinociceptive
KW - Docosahexaenoic acid
KW - Gastric injury
KW - Indomethacin
KW - Interaction
UR - http://www.scopus.com/inward/record.url?scp=84898669871&partnerID=8YFLogxK
U2 - 10.1016/j.pbb.2014.03.015
DO - 10.1016/j.pbb.2014.03.015
M3 - Artículo
C2 - 24657518
AN - SCOPUS:84898669871
SN - 0091-3057
VL - 122
SP - 74
EP - 81
JO - Pharmacology Biochemistry and Behavior
JF - Pharmacology Biochemistry and Behavior
ER -